Top Page
Vita Life Sciences Limited
(Sydney:VLS)
Vita Life Sciences Limited (VLS) vs. iShares MSCI Australia ETF (EWA)
Vita Life Sciences Limited Business Overview & Revenue Model
Vita Life Sciences Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 85.60M | 79.50M | 74.16M | 66.89M | 57.10M | 46.48M |
| Gross Profit | 51.65M | 47.24M | 42.60M | 39.74M | 34.81M | 29.27M |
| EBITDA | 12.83M | 13.46M | 13.10M | 11.37M | 11.71M | 8.88M |
| Net Income | 9.33M | 8.78M | 9.08M | 7.08M | 8.29M | 6.09M |
Balance Sheet | ||||||
| Total Assets | 74.64M | 71.89M | 59.81M | 51.80M | 45.27M | 39.10M |
| Cash, Cash Equivalents and Short-Term Investments | 29.40M | 28.60M | 24.63M | 15.69M | 15.89M | 14.48M |
| Total Debt | 2.25M | 517.00K | 387.00K | 601.00K | 373.00K | 2.07M |
| Total Liabilities | 22.03M | 19.61M | 16.48M | 15.30M | 14.85M | 14.66M |
| Stockholders Equity | 52.71M | 52.35M | 43.40M | 36.57M | 30.75M | 24.72M |
Cash Flow | ||||||
| Free Cash Flow | 9.17M | 5.96M | 12.32M | 7.54M | 5.73M | 7.46M |
| Operating Cash Flow | 10.09M | 6.16M | 12.98M | 7.68M | 5.89M | 7.54M |
| Investing Cash Flow | -920.00K | -198.00K | -660.00K | -139.00K | -155.00K | -89.00K |
| Financing Cash Flow | -8.56M | -2.99M | -2.88M | -3.10M | -4.39M | -3.03M |
Vita Life Sciences Limited Technical Analysis
Vita Life Sciences Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | AU$133.59M | 14.68 | 18.35% | 4.53% | 8.46% | -1.95% | |
62 Neutral | AU$44.40M | 12.41 | 6.90% | 2.99% | 0.13% | -12.90% | |
54 Neutral | AU$76.61M | 680.00 | 0.17% | ― | 17.82% | ― | |
41 Neutral | AU$20.04M | -1.34 | ― | ― | -47.30% | 82.53% | |
41 Neutral | AU$23.99M | -3.05 | -36.84% | ― | 45.30% | -24.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Vita Life Sciences Limited Corporate Events
Vita Life Sciences Limited has announced an update on its ongoing share buy-back program, which involves the repurchase of ordinary fully paid securities. As of the latest update, the company has bought back a total of 62,798 securities before the previous day and an additional 82,943 securities on the previous day. This buy-back initiative is part of Vita Life Sciences’ strategy to optimize its capital structure and potentially enhance shareholder value.
Vita Life Sciences Limited has announced an update on its ongoing share buy-back program, with a total of 62,798 ordinary fully paid securities bought back as of June 24, 2025. This strategic move is part of the company’s efforts to optimize its capital structure and potentially enhance shareholder value, reflecting a proactive approach to managing its financial resources.
Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of June 19, 2025, the company has bought back a total of 61,559 securities, with 9,745 purchased on the previous day. This buy-back initiative is part of the company’s efforts to manage its capital structure and potentially enhance shareholder value.
Vita Life Sciences Limited has announced an update on its ongoing buy-back program, revealing the purchase of 16,995 ordinary fully paid securities on the previous day, bringing the total number of securities bought back to 34,819. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting a proactive approach in managing its financial resources.
Vita Life Sciences Limited has announced its financial guidance for the first half of 2025, projecting a revenue growth of 14-16% compared to the previous year, driven by strong performance in its core markets. The company is investing in its brands and marketing capabilities to enhance its competitive position and is optimistic about continued growth and value creation for shareholders.
Vita Life Sciences Limited has announced a daily update regarding its ongoing on-market buy-back of ordinary fully paid securities, with a total of 29,060 securities bought back on the previous day. This buy-back strategy is part of the company’s efforts to manage its capital structure and could potentially enhance shareholder value by reducing the number of shares outstanding.
Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program. As of June 5, 2025, the company has bought back a total of 5,759 ordinary fully paid securities, with 454 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program, where it recently bought back 5,305 ordinary fully paid securities. This buy-back initiative is part of the company’s strategy to optimize its capital structure and enhance shareholder value, reflecting a proactive approach to managing its financial resources and reinforcing its market position.
Vita Life Sciences Limited has announced a new on-market buy-back of its ordinary fully paid securities, as indicated by its ASX security code VLS. This strategic move is likely aimed at optimizing the company’s capital structure and potentially enhancing shareholder value, reflecting a proactive approach to managing its financial resources.
Vita Life Sciences Limited announced that all resolutions proposed at its 2025 Annual General Meeting were successfully passed. Key resolutions included the approval of the remuneration report, the re-election of Director Mr. Henry Townsing, an increase in the aggregate annual remuneration for non-executive directors, and a share buy-back initiative. These decisions reflect the company’s strategic direction and commitment to enhancing shareholder value, potentially impacting its financial strategies and governance structure.
Vita Life Sciences Limited has announced the final notification of its on-market buy-back program, purchasing a total of 1,218,581 ordinary fully paid securities for a consideration of AUD 2,309,095.17. This buy-back reflects the company’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and signaling confidence in its financial health.
Vita Life Sciences Limited has announced an update regarding its ongoing buy-back program, where a total of 1,218,101 securities have been bought back prior to the previous day, with an additional 86 securities bought back on the previous day. This buy-back initiative reflects the company’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and signaling confidence in its financial stability.
Vita Life Sciences Limited has announced a daily update on its ongoing on-market buy-back program. As of the latest update, the company has repurchased a total of 1,218,101 ordinary fully paid securities. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Vita Life Sciences Limited announced a change in the director’s interest, with Director Peter Osborne acquiring 11,090 ordinary shares through an on-market trade, increasing his total holdings to 41,184 shares. This acquisition reflects a potential vote of confidence in the company’s future prospects and could positively influence stakeholder perceptions regarding the company’s market position and operational strategies.
Vita Life Sciences Limited has announced an update regarding its ongoing share buy-back program. As of May 6, 2025, the company has repurchased a total of 1,152,511 ordinary fully paid securities, with 15,999 bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.